Allergy & Immunology
Report: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
29 Oct, 2020 | 09:08h | UTCRobust neutralizing antibodies to SARS-CoV-2 infection persist for months – Science
Commentary on Twitter
Just published @ScienceMagazine. >30,000 people w/mild to moderate #COVID19 have excellent IgG antibody titers for several months. No disappearing act. Important??https://t.co/4kCZY8qcmo @MountSinaiNYC @FatimaAmanat @DrDavidReich @florian_krammer @IcahnMountSinai et al
, pic.twitter.com/B3LJ6JaBDa— Eric Topol (@EricTopol) October 28, 2020
SARS-CoV-2 antibodies detectable up to seven months post COVID-19 onset
27 Oct, 2020 | 09:44h | UTC
Commentary on Twitter
Neutralizing antibodies to SARS-CoV-2 Spike RBD, 40-199 days after symptom end:
– ~90% of patients have
– ~75% of them (~68%) have high titre (>300)
– no age difference
– higher in hospital cases and males
– lower with steroidsShould last a few years.https://t.co/OYZV6gRfyA https://t.co/Zdhj3W7yGw pic.twitter.com/eTUF870q05
— ice9 (@__ice9) October 24, 2020
Understanding protection from SARS-CoV-2 by studying reinfection
27 Oct, 2020 | 09:42h | UTCUnderstanding protection from SARS-CoV-2 by studying reinfection – Nature Medicine
COVID-19 antibody responses are related to the severity of symptoms
27 Oct, 2020 | 09:43h | UTCCommentaries: Studies show long-term COVID-19 immune response – CIDRAP AND COVID-19 immunity may be related to the severity of one’s symptoms, study finds – CTV News
Commentary on Twitter
A new paper @NatureMicrobiol shows the neutralizing antibody response to #SARSCoV2 is proportional to severity of illness, with longitudinal assessment, including a cohort of health care workers https://t.co/Ie4LAP8GZx @KingsCollegeLon and collaborators
— Eric Topol (@EricTopol) October 26, 2020
Review: Prospects for a safe COVID-19 vaccine
27 Oct, 2020 | 09:41h | UTCProspects for a safe COVID-19 vaccine – Science Translational Medicine
Perspective: The race to make COVID antibody therapies cheaper and more potent
25 Oct, 2020 | 23:43h | UTCThe race to make COVID antibody therapies cheaper and more potent – Nature
Coronavirus vaccine volunteer in Brazil’s AstraZeneca trial dies – but authorities say trial to continue
23 Oct, 2020 | 09:08h | UTCSee also: AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue – Reuters AND Expert reaction to media reports suggesting a person in Brazil who was taking part in the Brazil arm of the Oxford/AstraZeneca vaccine trial has died – Science Media Centre
SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates
22 Oct, 2020 | 09:36h | UTCSARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates – The Lancet
Commentary: The COVID-19 vaccine pipeline – News Medical
Commentary on Twitter
NEW Review—G Poland, I Ovsyannikova & R Kennedy @MayoClinic discuss what is currently known about human humoral & cellular immune responses to SARS-CoV-2 & relate this knowledge to the #COVID19 vaccines currently in phase 3 clinical trials https://t.co/eDkFq4WStA pic.twitter.com/hfw6yjviym
— The Lancet (@TheLancet) October 14, 2020
Perspective: Immunity and Re-Infection
22 Oct, 2020 | 09:34h | UTCImmunity and Re-Infection – Science Translational Medicine
‘Super antigens’ tied to mysterious COVID-19 syndrome in children
21 Oct, 2020 | 09:21h | UTC‘Super antigens’ tied to mysterious COVID-19 syndrome in children – National Geographic
Answering key questions about COVID-19 vaccines
18 Oct, 2020 | 23:10h | UTCAnswering Key Questions About COVID-19 Vaccines – JAMA
Commentary on Twitter
Many individuals are hesitant about receiving #COVID19 vaccines. It is critical that clinicians stay well informed about emerging data so that they can help patients make sound decisions https://t.co/1QDwOKuDqc @JesseGoodmanMD @ImmunizeOrg @pharmacists
— JAMA (@JAMA_current) October 16, 2020
Review: Why and how vaccines work
16 Oct, 2020 | 09:32h | UTCWhy and How Vaccines Work – Cell
Commentary on Twitter
Why and how vaccines work, including how the covid-19 vaccines are positioned, new adjuvants
New @CellCellPress by @VirusesImmunity and @SaadOmer3 https://t.co/ydGfLJh0Uv pic.twitter.com/8niIaMVlAQ— Eric Topol (@EricTopol) October 15, 2020
Pediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection: An overview
15 Oct, 2020 | 09:21h | UTC
Coronavirus vaccine: What we know so far – a comprehensive guide by academic experts
15 Oct, 2020 | 09:17h | UTC
Podcast: Ten things every new doctor should know about drug reactions
15 Oct, 2020 | 09:02h | UTCTen Things Every New Doctor Should Know About Drug Reactions – JAMA
Genomic evidence for reinfection with SARS-CoV-2: A case study
14 Oct, 2020 | 09:39h | UTCGenomic evidence for reinfection with SARS-CoV-2: a case study – The Lancet Infectious Diseases
Commentaries: First Case Of COVID-19 Reinfection In The US Confirmed; Exposure to Virus May Not Guarantee Protective Immunity, Says New Lancet Study – Health Policy Watch AND What reinfections mean for COVID-19 – The Lancet Infectious Diseases AND You can get reinfected with Covid-19 but still have immunity. Let’s explain. – Vox AND A 25-Year-Old Nevada Man Got COVID-19 Twice. Here’s What We Know—and Don’t Know—About Reinfection – TIME
Related: Dutch woman dies after catching Covid-19 twice, the first reported reinfection death – CNN
Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant
14 Oct, 2020 | 09:31h | UTCJohnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant – STAT
News Release: Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials
Commentaries: Johnson & Johnson ‘Pauses’ COVID-19 Vaccine Trial Due To Unexplained Illness In Participant; Eli Lilly Reportedly Suspending Trial Of Antibody Treatment – Health Policy Watch AND Johnson & Johnson pauses Covid-19 vaccine trial after ‘unexplained illness’ – CNN
Non-respiratory presentations of COVID-19, a clinical review
14 Oct, 2020 | 09:33h | UTC
Monoclonal antibody trial halted for safety concern
14 Oct, 2020 | 09:30h | UTCMonoclonal Antibody Trial Halted for Safety Concern – Brief19
[Abstract Only] Randomized trials: Efficacy and safety of a plant-derived influenza vaccine in adults
14 Oct, 2020 | 09:23h | UTCEfficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW—First large-scale studies of plant-derived, quadrivalent, virus-like particle influenza vaccine show substantial protection against respiratory illness & influenza-like illness caused by influenza viruses in adults: two randomised phase 3 trials https://t.co/oQbs2uJTXY pic.twitter.com/C6b6Qi6qZ7
— The Lancet (@TheLancet) October 13, 2020
[News release – not published yet] Eli Lilly says its monoclonal antibody cocktail is effective in treating Covid-19
9 Oct, 2020 | 09:09h | UTCEli Lilly says its monoclonal antibody cocktail is effective in treating Covid-19 – STAT
5 things to know about a COVID vaccine: It won’t be a ‘magic wand’
8 Oct, 2020 | 09:05h | UTC5 Things to Know About a COVID Vaccine: It Won’t Be a ‘Magic Wand’ – Kaiser Health News
How the leading coronavirus vaccines work
8 Oct, 2020 | 09:06h | UTCHow the leading coronavirus vaccines work – The Conversation
Related: SARS-CoV-2 Vaccine Development: Current Status – Mayo Clinic Proceedings
Long-term health consequences of COVID-19
6 Oct, 2020 | 00:58h | UTCLong-term Health Consequences of COVID-19 – JAMA
Commentary on Twitter
Persistent post-COVID symptoms could be the from direct tissue invasion by the virus, profound inflammation & cytokine storm, related immune system damage, hypercoagulable state, or some combination https://t.co/G8tI9U3TaL @CarlosdelRio7 lfcollins_md @PreetiNMalani
— JAMA (@JAMA_current) October 5, 2020
Systematic review: Sublingual immunotherapy for asthma
6 Oct, 2020 | 00:11h | UTCSublingual immunotherapy for asthma – Cochrane Library
Summary: Sublingual immunotherapy for asthma – Cochrane Library